Summit Trail Advisors LLC lessened its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 11.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 754 shares of the medical instruments supplier’s stock after selling 98 shares during the quarter. Summit Trail Advisors LLC’s holdings in West Pharmaceutical Services were worth $248,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors also recently modified their holdings of the company. Pitcairn Co. grew its holdings in shares of West Pharmaceutical Services by 3.4% during the 1st quarter. Pitcairn Co. now owns 875 shares of the medical instruments supplier’s stock worth $346,000 after purchasing an additional 29 shares in the last quarter. Copperwynd Financial LLC grew its holdings in shares of West Pharmaceutical Services by 4.0% during the 4th quarter. Copperwynd Financial LLC now owns 778 shares of the medical instruments supplier’s stock worth $274,000 after purchasing an additional 30 shares in the last quarter. Clearbridge Investments LLC lifted its position in shares of West Pharmaceutical Services by 0.7% during the 1st quarter. Clearbridge Investments LLC now owns 4,495 shares of the medical instruments supplier’s stock worth $1,779,000 after buying an additional 31 shares during the period. RFG Advisory LLC lifted its position in shares of West Pharmaceutical Services by 2.3% during the 1st quarter. RFG Advisory LLC now owns 1,465 shares of the medical instruments supplier’s stock worth $580,000 after buying an additional 33 shares during the period. Finally, Ballentine Partners LLC lifted its position in shares of West Pharmaceutical Services by 4.7% during the 2nd quarter. Ballentine Partners LLC now owns 742 shares of the medical instruments supplier’s stock worth $244,000 after buying an additional 33 shares during the period. Institutional investors and hedge funds own 93.90% of the company’s stock.
West Pharmaceutical Services Price Performance
West Pharmaceutical Services stock opened at $309.85 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.34 and a quick ratio of 1.68. The company has a market capitalization of $22.57 billion, a PE ratio of 40.88, a price-to-earnings-growth ratio of 10.58 and a beta of 1.01. West Pharmaceutical Services, Inc. has a one year low of $265.00 and a one year high of $413.70. The business has a 50 day simple moving average of $302.72 and a 200 day simple moving average of $336.46.
Insider Buying and Selling
In related news, VP Charles Witherspoon sold 1,029 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the completion of the transaction, the vice president now owns 1,478 shares in the company, valued at approximately $443,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.53% of the stock is owned by corporate insiders.
West Pharmaceutical Services Profile
West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
See Also
- Five stocks we like better than West Pharmaceutical Services
- Roth IRA Calculator: Calculate Your Potential Returns
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- The Basics of Support and Resistance
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- How to Invest in Insurance Companies: A Guide
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.